European CHMP recommends approval of zanamivir solution for infusion (Dectova) for the treatment of complicated and potentially life-threatening influenza

This opinion summary advises that it will be available as a 10 mg/ml solution for infusion for the treatment of complicated and potentially life-threatening influenza A or B virus infection in patients aged ≥6 months when other anti-virals, including inhaled zanamivir, are not suitable for the patient.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news